Skip to search formSkip to main contentSkip to account menu

MBC 215

Known as: MBC-215 
National Institutes of Health

Related topics

Related topics

1 relation
Kathon 886

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Abstract P3-11-04: A phase II study of pembrolizumab, letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer
Background: The combination of CDK4/6 inhibitor and aromatase inhibitor is the current standard of care therapy for patients with… 
2017
2017
State-of-the-Art Update: CDK4/6 Inhibitors in ER+ Metastatic Breast Cancer
Introduction Anti-CDK4/6 agents inhibit the phosphorylation of the retinoblastoma (Rb) tumor suppressor, which promotes Rb-E2F… 
2017
2017
Abstract OT2-01-03: Phase II Trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on…
Background: The combination of palbociclib and letrozole has become the standard of care for patients with newly diagnosed… 
2016
2016
Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer.
AIM We conducted a phase I study to determine the maximum tolerated dose (MTD) and recommended dose (RD) of triweekly… 
2016
2016
Combination of trastuzumab, oxaliplatin, and docetaxel as first-line treatment in HER2-positive metastatic breast cancer patients: First-step results of a phase II trial (HOT trial).
1132 Background: The addiction of trastuzumab to standard chemotherapy has improved the outcome of HER-2-positive metastatic… 
2013
2013
Abstract PD1-4: A phase I study of BKM120 and fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer
Background BKM120, a pan-Phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant (F) induced synergistic… 
2011
2011
PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase…
Introduction: Fulvestrant is an effective endocrine therapy in patients with ER+ metastatic breast cancer (MBC) that has become… 
2011
2011
Use of clinical and treatment factors to predict survival outcome in nonmetastatic metaplastic breast cancer.
11 Background: Although metaplastic breast cancer (MBC) represents < 1% of breast cancer, stem cell research has stimulated… 
2009
2009
Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast…
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #3131 Background: Preclinical data suggest that… 
2006
2006
Efficacy of New Benzimidazole Fungicides Against Sensitive and Benomyl-Resistant Botrytis cinerea
Chiba, M., and Northover, J. 1988. Efficacy of new benzimidazole fungicides against sensitive and benomyl-resistant Botrytis… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)